BPC-157 for tendons (UK evidence review): what the rodent data actually shows

·6 min read

BPC-157's tendon literature is almost entirely rodent-based. Krivic et al. and Staresinic et al. reported that transected rat Achilles tendons treated with BPC-157 (typically 10 µg/kg or 10 ng/kg intraperitoneally or locally) showed faster functional recovery, improved tenocyte outgrowth in vitro, and better organised collagen fibres on histology versus controls.

Chang et al. extended this to cultured tendon fibroblasts, showing dose-dependent increases in cell migration and F-actin formation, plausibly via upregulation of the growth-hormone receptor on tenocytes. The mechanism is consistent, but every published tendon study is preclinical.

There are no completed randomised human trials of BPC-157 for tendinopathy. UK researchers should treat any human anecdote as uncontrolled. Dosing conventions used in laboratory work are summarised in the BPC-157 dosage UK guide, including U-100 syringe units for a 5 mg vial.

BPC-157 is not licensed by the MHRA and is prohibited in-competition under the WADA S0 category. It is supplied in the UK for laboratory research only.

Editorial partner

Referenced supplier: PeptidesUK4U

Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.

  • HPLC-tested batches
  • Batch-level CoAs
  • UK cold-chain despatch
Why we cite them
  1. 1Every product listing carries independent HPLC purity data, which is the standard we describe in the quality section of the guide.
  2. 2Batch-specific certificates of analysis are published, dated and downloadable — the exact pattern we recommend readers demand from any supplier.
  3. 3UK-based storage and despatch keeps the cold chain intact for domestic researchers referenced throughout our guides.

Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.